Multifocal corneal ablation (Supracor) in hyperopic presbyopia: 1-year results in a cross-sectional study.
To evaluate the efficacy and safety of the multifocal excimer laser corneal ablation profile (the Supracor procedure) in hyperopic presbyopia 1 year after laser treatment. This prospective, consecutive, one-center, cross-sectional study included 20 patients with hyperopic presbyopia 1 year after treatment with the Supracor procedure. The main outcome measures were monocular uncorrected distance visual acuity (UDVA) and uncorrected near visual acuity (UNVA), photopic contrast sensitivity (Pelli-Robson charts), patient satisfaction, and functioning at 12 months. Thirty-nine eyes of 20 patients (mean age 59 ± 7.2 years) were treated. Mean UDVA improved from 0.56 ± 0.31 (mean 0.34 logMAR) preoperatively to 0.9 ± 0.15 (mean 0.06 logMAR) 12 months after surgery. Mean UNVA increased from 0.15 ± 0.07 (mean 0.84 logMAR) before surgery to 0.62 ± 0.24 (mean 0.23 logMAR) 12 months after treatment. Four eyes lost 2 lines of corrected distance visual acuity (10.3%). Monocular photopic contrast sensitivity was within age-correlated normal range (Pelli-Robson chart, mean contrast sensitivity 1.83 ± 0.18). A total of 75% of the patients would undergo Supracor again (1 not, 4 perhaps). The most frequently reported side effects were increased glare, reduced distance vision, and fluctuations in vision. Most patients used artificial tears. One year after Supracor, UDVA and UNVA improved markedly, photopic contrast sensitivity was in normal age-correlated range, and the majority of patients (75%) was satisfied with the results. Side effects like loss of distance vision, fluctuations of vision, and increased glare have a greater influence on patient satisfaction than the improvement of spectacle-free near vision.